MISSISSAUGA, ON, Feb. 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported operational and financial results for the second quarter of fiscal 2009, ended December 31, 2008.
"During the quarter we prepared to initiate our two randomized Phase II trials for nimotuzumab, which concentrate on two forms of cancer typically treated with radiation-containing regimens. These trials are the cornerstone of YM's registration program for this drug, driven by prior data indicating nimotuzumab's potential to maximize the benefits of radiotherapy while avoiding the toxic side-effects of the other EGFR-targeting drugs," said David Allan, Chairman and CEO of YM BioSciences. "In addition to YM's internal clinical strategy, we continue to benefit from the network of cooperative relationships for the development of nimotuzumab which is undertaking a broad, late-stage, clinical program for this drug."
Highlights for the second quarter of Fiscal 2009: - YM received clearance from Canadian regulatory authorities to initiate two Phase II, double-blind, randomized trials for its EGFR- targeting antibody, nimotuzumab, in combination with radiation-based treatments. Enrolment for both trials, one in patients with non-small cell lung cancer (NSCLC) and the other in patients with brain metastases from NSCLC, is expected to be initiated in Canada in the first quarter of calendar 2009 and YM anticipates expanding the trials into other countries. - The National Cancer Centre of Singapore (NCCS) selected nimotuzumab for evaluation in the adjuvant setting in a multinational Phase III trial of more than 700 patients with cancers of the head and neck, citing the drug's preferential safety profil
|SOURCE YM BioSciences Inc.|
Copyright©2009 PR Newswire.
All rights reserved